Dataset Information

Proof-of-Concept and Randomized, Placebo-Controlled Trials of an Fcrn Inhibitor, Batoclimab, for Thyroid Eye Disease.

ABSTRACT:

Context

Inhibition of the neonatal fragment crystallizable receptor (FcRn) reduces pathogenic thyrotropin receptor antibodies (TSH-R-Ab) that drive pathology in thyroid eye disease (TED).

Objective

We report the first clinical studies of an FcRn-inhibitor, batoclimab, in TED.

Design

Proof-of-concept (POC) and randomized, double-blind placebo-controlled trials.

Setting

Multicenter.

Participants

Patients with moderate-to-severe, active TED.

Intervention

In the POC trial, patients received weekly subcutaneous injections of batoclimab 680 mg for 2 weeks, followed by 340 mg for 4 weeks. In the double-blind trial, patients were randomized 2:2:1:2 to weekly batoclimab (680 mg, 340 mg, 255 mg) or placebo for 12 weeks.

Main outcome

Change from baseline in serum anti-TSH-R-Ab and total IgG (POC); 12-week proptosis response (randomized trial).

Results

The randomized trial was terminated due to an unanticipated increase in serum cholesterol; therefore, data from 65 of the planned 77 patients were analyzed. Both trials showed marked decreases in pathogenic anti-TSH-R-Ab and total IgG serum levels (P<0.001) with batoclimab. In the randomized trial, there was no statistically significant difference with batoclimab versus placebo in proptosis response at 12 weeks, although significant differences were observed at several earlier timepoints. In addition, orbital muscle volume decreased (P<0.03) at 12 weeks, while quality of life (appearance subscale) improved (P<0.03) at 19 weeks in the 680-mg group. Batoclimab was generally well tolerated, with albumin reductions and increases in lipids that reversed upon discontinuation.

Conclusions

These results provide insight into the efficacy and safety of batoclimab and support its further investigation as a potential therapy for TED.

SUBMITTER: Kahaly GJ

PROVIDER: S-EPMC10655547 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.

Kahaly George J GJ Dolman Peter J PJ Wolf Jan J Giers Bert C BC Elflein Heike M HM Jain Amy P AP Srinivasan Ashok A Hadjiiski Lubomir L Jordan David D Bradley Elizabeth A EA Stan Marius N MN Eckstein Anja A Pitz Susanne S Vorländer Christian C Wester Sara T ST Nguyen John J Tucker Nancy N Sales-Sanz Marco M Feldon Steven E SE Nelson Christine C CC Hardy Isabelle I Abia-Serrano Maravillas M Tedeschi Philip P Janes Jonathan M JM Xu Jing J Vue Peter P Macias William L WL Douglas Raymond S RS

The Journal of clinical endocrinology and metabolism 20231101 12

<h4>Context</h4>Inhibition of the neonatal fragment crystallizable receptor (FcRn) reduces pathogenic thyrotropin receptor antibodies (TSH-R-Ab) that drive pathology in thyroid eye disease (TED).<h4>Objective</h4>We report the first clinical studies of an FcRn inhibitor, batoclimab, in TED.<h4>Design</h4>Proof-of-concept (POC) and randomized, double-blind placebo-controlled trials.<h4>Setting</h4>Multicenter.<h4>Participants</h4>Patients with moderate-to-severe, active TED.<h4>Intervention</h4>I ...[more]

PMID: 37390454

Similar Datasets

Project description:BackgroundWe assessed the impact of retinoid X receptor (RXR) agonist bexarotene on brain amyloid measured by amyloid imaging in patients with Alzheimer's disease (AD) in a proof-of-concept trial.MethodsTwenty patients with AD [Mini Mental State Examination (MMSE) score 10-20 inclusive] with positive florbetapir scans were randomized to receive 300 mg of bexarotene or placebo for 4 weeks. The amyloid imaging result was the primary outcome. Whole-population analyses and prespecified analyses by genotype [apolipoprotein E ε4 (ApoE4) carriers and ApoE4 noncarriers] were conducted. Secondary outcomes included scores on the Alzheimer's Disease Assessment Scale-Cognitive subscale, Alzheimer's Disease Cooperative Study-Activities of Daily Living scale, MMSE, Clinical Dementia Rating scale, and Neuropsychiatric Inventory. Serum amyloid-β (Aβ) peptide sequences Aβ1-40 and Aβ1-42 measurements were collected as biomarker outcomes.ResultsThere was no change in the composite or regional amyloid burden when all patients were included in the analysis. ApoE4 noncarriers showed a significant reduction in brain amyloid on the composite measure in five of six regional measurements. No change in amyloid burden was observed in ApoE4 carriers. There was a significant association between increased serum Aβ1-42 and reductions in brain amyloid in ApoE4 noncarriers (not in carriers). There were significant elevations in serum triglycerides in bexarotene-treated patients. There was no consistent change in any clinical measure.ConclusionsThe primary outcome of this trial was negative. The data suggest that bexarotene reduced brain amyloid and increased serum Aβ1-42 in ApoE4 noncarriers. Elevated triglycerides could represent a cardiovascular risk, and bexarotene should not be administered outside a research setting. RXR agonists warrant further investigations as AD therapies.Trial registrationClinicalTrials.gov identifier NCT01782742 . Registered 29 January 2013.